Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$72.1MCash on Hand
30.7mo Cash Runway
Follow SLN by emailGet an email when SLN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SLN, unsubscribe in one click. Privacy
📣 What SLN Says Is Next
first quarter of 2027 · “The transaction is expected to close in the first quarter of 2027, and is subject to Silence shareholder approval, sanction by the High Court of Justice of England and Wales (the “Court”) and other customary closing conditions, including regulatory approvals.”
Company press release, Oct 19, 2026 · SEC filing
in 2026 · “HoFH=Homozygous familial hypercholesterolemia Ph1 data presentations anticipated in 2026 Silencing diseases through precision engineered medicines created with proprietarysiRNA technology”
Company press release, Mar 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Earnings Reported Q3 2026 results: cash and equivalents of $247.7 million, R&D expenses of $9.3 million versus $20.5 million a year earlier, G&A of $4.9 million, and a net loss of $12.4 million, or $0.08 per share. Form 8-K · SEC filing · Press release
Oct 19, 2026 ·
Deal Silence Therapeutics agreed to be acquired by Merck KGaA, Darmstadt, Germany for $20.00 in cash per ADS, or $6.6667 per ordinary share, via a U.K. scheme of arrangement. The deal is subject to shareholder approval, court sanction and regulatory approvals, with closing expected in Q1 2027. Form 8-K · SEC filing · Press release
Aug 12, 2026 ·
Financing Silence Therapeutics priced a public offering of 12,962,963 ADSs (38,888,889 ordinary shares) at $13.50 per ADS, for gross proceeds of $175,000,000.50. Underwriters have a 30-day option to buy 1,944,444 more ADSs. Form 424B5 · SEC filing
Aug 12, 2026 ·
Financing Silence Therapeutics priced an underwritten offering of 12,962,963 ADSs at $13.50 per ADS, with a 30-day option for 1,944,444 more. Net proceeds are expected to be about $164.0 million, or $188.7 million if the option is fully exercised. Closing is expected August 13, 2026. Form 8-K · SEC filing · Press release
Aug 10, 2026 ·
Earnings Reported Q2 2026 net loss of $12.3 million ($0.09 per share), down from $27.4 million a year earlier, as R&D fell to $9.1 million from $17.6 million. Cash and equivalents were $72.1 million at June 30, 2026. Form 8-K · SEC filing · Press release
Aug 10, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 10, 2026 ·
Clinical trial Announced positive topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera. Primary endpoint met with response rates of 88% for divesiran versus 19% for placebo (p<0.0001). Phase 3 trial of Q12W dosing vs. placebo expected to start in 1H'27. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Sep 2026 · Phase 1/2 · Active Trial · Study to Assess SLN124 in Patients With Polycythemia Vera Registry primary completion date, not a results date
Jan 2024 · Phase 2 · Results Expected · Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events Registry primary completion date, not a results date
Aug 2023 · Phase 1 · Results Expected · Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a) Registry primary completion date, not a results date
May 2023 · Phase 1 · Results Expected · A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome Registry primary completion date, not a results date
Mar 2021 · Early Phase 1 · Results Expected · A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers Registry primary completion date, not a results date
Aug 2015 · Phase 1/2 · Results Expected · Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
SLN holds $72.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $7M/quarter from operations,
an estimated runway of 30.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:24 · Moderate
Cash runway 31 months
ATM program on file since Aug 2026 +15
Shelf registration (S-3, May 2026) +10
Company says cash lasts until 2028 -15Based on this evaluation, the Group believes that its current cash and cash equivalents as of September 30, 2026 are sufficient to fund its forecasted operating expenses and capital expenditure requirements at least until 2028.10-Q, Nov 2026
Share count 186,609,073 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full SLN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SLN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.